OTC Markets OTCQX - Delayed Quote USD

Roche Holding AG (RHHBY)

Compare
39.72 +0.01 (+0.03%)
At close: September 10 at 4:00 PM EDT
Loading Chart for RHHBY
DELL
  • Previous Close 39.71
  • Open 39.63
  • Bid 39.67 x 300400
  • Ask 39.70 x 40000
  • Day's Range 39.37 - 39.75
  • 52 Week Range 29.20 - 42.43
  • Volume 316,428
  • Avg. Volume 1,872,859
  • Market Cap (intraday) 254.663B
  • Beta (5Y Monthly) 0.15
  • PE Ratio (TTM) 20.27
  • EPS (TTM) 1.96
  • Earnings Date Jul 25, 2024
  • Forward Dividend & Yield 1.35 (3.40%)
  • Ex-Dividend Date Mar 14, 2024
  • 1y Target Est 41.78

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.

www.roche.com

103,605

Full Time Employees

December 31

Fiscal Year Ends

Recent News: RHHBY

View More

Performance Overview: RHHBY

Trailing total returns as of 9/11/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

RHHBY
14.29%
MSCI WORLD
12.17%

1-Year Return

RHHBY
15.53%
MSCI WORLD
0.00%

3-Year Return

RHHBY
5.54%
MSCI WORLD
13.86%

5-Year Return

RHHBY
36.75%
MSCI WORLD
63.11%

Compare To: RHHBY

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: RHHBY

View More

Valuation Measures

Annual
As of 9/10/2024
  • Market Cap

    256.36B

  • Enterprise Value

    286.72B

  • Trailing P/E

    20.26

  • Forward P/E

    13.12

  • PEG Ratio (5yr expected)

    1.24

  • Price/Sales (ttm)

    3.56

  • Price/Book (mrq)

    7.38

  • Enterprise Value/Revenue

    3.99

  • Enterprise Value/EBITDA

    13.66

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    17.53%

  • Return on Assets (ttm)

    12.49%

  • Return on Equity (ttm)

    36.36%

  • Revenue (ttm)

    60.58B

  • Net Income Avi to Common (ttm)

    10.62B

  • Diluted EPS (ttm)

    1.96

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    8.81B

  • Total Debt/Equity (mrq)

    110.04%

  • Levered Free Cash Flow (ttm)

    8.13B

Research Analysis: RHHBY

View More

Company Insights: RHHBY

Research Reports: RHHBY

View More

People Also Watch